Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Prognostic diagnosis marker Claudin 22 of ovarian cancer and application of prognostic diagnosis marker Claudin 22

A technology for diagnosing marker and ovarian cancer, applied in the field of clinical analysis, can solve the problems of no other family members, no specific Claudin22 related to the prognosis of gynecological tumors, etc.

Active Publication Date: 2021-01-15
ZHEJIANG CANCER HOSPITAL
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is currently no research related to the occurrence and development of other family members and tumors, let alone the research on the prognosis of Claudin22 and gynecological tumors. Therefore, this application will be based on the previous research on the relationship between Claudin22 and gynecological tumors and Clinical application value for research and development

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Prognostic diagnosis marker Claudin 22 of ovarian cancer and application of prognostic diagnosis marker Claudin 22
  • Prognostic diagnosis marker Claudin 22 of ovarian cancer and application of prognostic diagnosis marker Claudin 22
  • Prognostic diagnosis marker Claudin 22 of ovarian cancer and application of prognostic diagnosis marker Claudin 22

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023]Example 1 Sample preparation

[0024]1. Sample collection

[0025]This study collected 38 patients who were diagnosed with epithelial ovarian cancer at Zhejiang Cancer Hospital from October 2008 to July 2014. All patients received the standard treatment plan: initial cytoreductive surgery or initial staging Surgery plus 6-8 courses of first-line chemotherapy (platinum combined with paclitaxel) after surgery. According to the type of tumor tissue, they are divided into: 1. Serous adenocarcinoma; 2. Mucinous adenocarcinoma; 3. Endometrioid adenocarcinoma; 4. Clear cell Carcinoma; 5. Unclassified adenocarcinoma; 6. Transitional cell carcinoma; 7. Mixed cancer of two or more types. Carefully collect the clinicopathological data of each patient, and follow up the patients by telephone after treatment. The last follow-up time is April 2020, and the patient's follow-up time is 11-134 months.

[0026]2. In this study, the definitions of ovarian cancer patients' recurrence, chemotherapy sensiti...

Embodiment 2

[0037]Example 2 Experimental method

[0038]1. Immunohistochemistry

[0039]1) After two senior pathologists performed multiple slices of paraffin sections, follow-up experiments were carried out.

[0040]2) Deparaffinization and hydration: Soak the slices in xylene solution 3 times for 10 minutes each time. After taking it out, soak in 95% alcohol for 5 minutes, and then soak in 75% alcohol for 5 minutes. Finally, soak in 50% alcohol for 5 minutes. Take out the slices and soak in distilled water.

[0041]3) Blocking endogenous peroxidase: immerse the dewaxed and hydrated section in a methanol solution containing 3% hydrogen peroxide for 15 minutes. Then rinse with PBS solution 3 times, 5 minutes each time.

[0042]4) Microwave antigen retrieval: immerse the slices in a buffer containing EDTA and citrate, and place them in a microwave oven, 100% power for 8 minutes, 80% power for 6 minutes, and 60% power for 6 minutes; each microwave Replenish buffer in time afterwards. After cooling, the sections...

Embodiment 3

[0055]Example 3 Claudin22 expression is associated with poor prognosis

[0056]According to the above definition, the expression of Claudin22 in the case was subjected to immunohistochemical experiments and scoring statistics. The specific results are shown in Table 2.

[0057]Table 2 Correlation between Claudin22 expression and clinicopathological parameters

[0058]

[0059]Claudin22 is mainly expressed in the cytoplasm of ovarian cancer cells, and the coloration is brown or brown (figure 1 ). We found that 56.3% (18 / 32) of poorly differentiated ovarian cancers with low expression of Claudin22 were higher than 43.7% (14 / 32) of well-differentiated patients, a statistical difference (P=0.047). In addition, from survival From a prognostic point of view, the PFS and OS of patients with ovarian cancer with low Claudin22 expression were significantly better than those with high Claudin22 expression (P=0.02, P=0.02,figure 2).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a prognosis marker Claudin 22 of ovarian cancer and application thereof, and firstly finds that the expression quantity of the ovarian cancer drug-resistant marker Claudin 22is related to the prognosis of ovarian cancer, specifically, in prognosis indexes such as no progression lifetime and total lifetime when Claudin 22 is highly expressed, ovarian cancer cases show poorprognosis, and prognosis accuracy is high. The discovery of the prognosis marker Claudin 22 provides prognosis prompts for clinical treatment of ovarian cancer, including chemotherapy and surgical treatment.

Description

Technical field[0001]The present invention belongs to the field of molecular biology, and specifically relates to the field of diagnosis / grading / staging and prognosis of cancer. More specifically, the present invention relates to the field of ovarian cancer. The invention also relates to the field of diagnosis, grading, staging and prognosis of ovarian cancer including the expression of biomarkers, and also provides relevant analysis reagents, diagnostic models, test kits and clinical analysis.Background technique[0002]Ovarian cancer is the gynecological tumor with the highest fatality rate among women in my country. According to the China Cancer Annual Report, there were approximately 52,100 new patients in 2015 and approximately 22,500 deaths from ovarian cancer in the same year. With the aging of the population in my country, the incidence of ovarian cancer is increasing year by year, and the age of onset has a trend of getting younger. Globally, the incidence of ovarian cancer r...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/577G01N33/574
CPCG01N33/577G01N33/57484G01N33/57449G01N2333/705
Inventor 施亮傅志勤杨悦周陈西俞婷婷鲁超黄萍
Owner ZHEJIANG CANCER HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com